-+ 0.00%
-+ 0.00%
-+ 0.00%

ANTENGENE ANNOUNCES FIRST PATIENT DOSED IN PHASE I ATTRACT STUDY EVALUATING ATG-201 (CD19 × CD3 TCE) FOR B CELL-MEDIATED AUTOIMMUNE DISEASES

Reuters·11/06/2026 00:30:00

Please log in to view news